Industry Research Reports

Home > Reports > Medical Care > Patient-derived Xenograft (PDX) Models - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Patient-derived Xenograft (PDX) Models - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Medical Care

Published: 2024-01-18

Pages: 126 Pages

Report ld: 2324933

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

The global market for Patient-derived Xenograft (PDX) Models was estimated to be worth US$ 331.6 million in 2023 and is forecast to a readjusted size of US$ 588.6 million by 2030 with a CAGR of 8.5% during the forecast period 2024-2030
Global top 5 manufacturers of patient-derived xenograft (PDX) models occupied for a share nearly 45 percent, key players are Crown Bioscience, Champions Oncology, Wuxi Apptec, EPO Berlin-Buch, and Oncodesign, etc. Geographically speaking, Asia Pacific holds the most of global market share, about 35%. North America holds about 30% of share, while Europe followed by nearly 20%. In terms of type, mouse model accounted for nearly 75%, and rat model accounted for a share of 25%,The application of patient-derived xenograft (PDX) models includes preclinical drug development and biomarker analysis. Preclinical drug development shares over 75%, while biomarker analysis shares about 20%.

Patient-derived Xenograft (PDX) Models Market Size

M= millions and B=billions

Report Scope
This report aims to provide a comprehensive presentation of the global market for Patient-derived Xenograft (PDX) Models, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Patient-derived Xenograft (PDX) Models by region & country, by Type, and by Application.

The Patient-derived Xenograft (PDX) Models market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Patient-derived Xenograft (PDX) Models.

Market Segmentation

Report Metric
Details
Report Title
Patient-derived Xenograft (PDX) Models - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Forecasted Market Size in 2030
US$ 588.6 million
CAGR(2024-2030)
8.5%
Market Size Available for Years
2019-2030
Global Patient-derived Xenograft (PDX) Models Companies Covered
Crown Bioscience, Champions Oncology, Wuxi Apptec, The Jackson Laboratory, EPO Berlin-Buch, Oncodesign, Xentech, Envigo, Charles River Laboratories, Pharmatest Services, Urosphere, MEDICILON, Horizon Discovery, Shanghai Model Organisms Center, GemPharmatech, LIDE Biotech
Global Patient-derived Xenograft (PDX) Models Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Patient-derived Xenograft (PDX) Models Market, Segment by Type
Mouse Model

Rat Model
Global Patient-derived Xenograft (PDX) Models Market, Segment by Application
Preclinical Drug development

Biomarker Analysis
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Patient-derived Xenograft (PDX) Models manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Patient-derived Xenograft (PDX) Models in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Patient-derived Xenograft (PDX) Models in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Patient-derived Xenograft (PDX) Models Product Introduction
    1.2 Global Patient-derived Xenograft (PDX) Models Market Size Forecast
    1.3 Patient-derived Xenograft (PDX) Models Market Trends & Drivers
        1.3.1 Patient-derived Xenograft (PDX) Models Industry Trends
        1.3.2 Patient-derived Xenograft (PDX) Models Market Drivers & Opportunity
        1.3.3 Patient-derived Xenograft (PDX) Models Market Challenges
        1.3.4 Patient-derived Xenograft (PDX) Models Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Patient-derived Xenograft (PDX) Models Players Revenue Ranking (2023)
    2.2 Global Patient-derived Xenograft (PDX) Models Revenue by Company (2019-2024)
    2.3 Key Companies Patient-derived Xenograft (PDX) Models Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Patient-derived Xenograft (PDX) Models Product Offered
    2.5 Key Companies Time to Begin Mass Production of Patient-derived Xenograft (PDX) Models
    2.6 Patient-derived Xenograft (PDX) Models Market Competitive Analysis
        2.6.1 Patient-derived Xenograft (PDX) Models Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Patient-derived Xenograft (PDX) Models Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Patient-derived Xenograft (PDX) Models as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Mouse Model
        3.1.2 Rat Model
    3.2 Global Patient-derived Xenograft (PDX) Models Sales Value by Type
        3.2.1 Global Patient-derived Xenograft (PDX) Models Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Patient-derived Xenograft (PDX) Models Sales Value, by Type (2019-2030)
        3.2.3 Global Patient-derived Xenograft (PDX) Models Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Preclinical Drug development
        4.1.2 Biomarker Analysis
    4.2 Global Patient-derived Xenograft (PDX) Models Sales Value by Application
        4.2.1 Global Patient-derived Xenograft (PDX) Models Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Patient-derived Xenograft (PDX) Models Sales Value, by Application (2019-2030)
        4.2.3 Global Patient-derived Xenograft (PDX) Models Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Patient-derived Xenograft (PDX) Models Sales Value by Region
        5.1.1 Global Patient-derived Xenograft (PDX) Models Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Patient-derived Xenograft (PDX) Models Sales Value by Region (2019-2024)
        5.1.3 Global Patient-derived Xenograft (PDX) Models Sales Value by Region (2025-2030)
        5.1.4 Global Patient-derived Xenograft (PDX) Models Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Patient-derived Xenograft (PDX) Models Sales Value, 2019-2030
        5.2.2 North America Patient-derived Xenograft (PDX) Models Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Patient-derived Xenograft (PDX) Models Sales Value, 2019-2030
        5.3.2 Europe Patient-derived Xenograft (PDX) Models Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Patient-derived Xenograft (PDX) Models Sales Value, 2019-2030
        5.4.2 Asia Pacific Patient-derived Xenograft (PDX) Models Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Patient-derived Xenograft (PDX) Models Sales Value, 2019-2030
        5.5.2 South America Patient-derived Xenograft (PDX) Models Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Patient-derived Xenograft (PDX) Models Sales Value, 2019-2030
        5.6.2 Middle East & Africa Patient-derived Xenograft (PDX) Models Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Patient-derived Xenograft (PDX) Models Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Patient-derived Xenograft (PDX) Models Sales Value
    6.3 United States
        6.3.1 United States Patient-derived Xenograft (PDX) Models Sales Value, 2019-2030
        6.3.2 United States Patient-derived Xenograft (PDX) Models Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Patient-derived Xenograft (PDX) Models Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Patient-derived Xenograft (PDX) Models Sales Value, 2019-2030
        6.4.2 Europe Patient-derived Xenograft (PDX) Models Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Patient-derived Xenograft (PDX) Models Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Patient-derived Xenograft (PDX) Models Sales Value, 2019-2030
        6.5.2 China Patient-derived Xenograft (PDX) Models Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Patient-derived Xenograft (PDX) Models Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Patient-derived Xenograft (PDX) Models Sales Value, 2019-2030
        6.6.2 Japan Patient-derived Xenograft (PDX) Models Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Patient-derived Xenograft (PDX) Models Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Patient-derived Xenograft (PDX) Models Sales Value, 2019-2030
        6.7.2 South Korea Patient-derived Xenograft (PDX) Models Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Patient-derived Xenograft (PDX) Models Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Patient-derived Xenograft (PDX) Models Sales Value, 2019-2030
        6.8.2 Southeast Asia Patient-derived Xenograft (PDX) Models Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Patient-derived Xenograft (PDX) Models Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Patient-derived Xenograft (PDX) Models Sales Value, 2019-2030
        6.9.2 India Patient-derived Xenograft (PDX) Models Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Patient-derived Xenograft (PDX) Models Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Crown Bioscience
        7.1.1 Crown Bioscience Profile
        7.1.2 Crown Bioscience Main Business
        7.1.3 Crown Bioscience Patient-derived Xenograft (PDX) Models Products, Services and Solutions
        7.1.4 Crown Bioscience Patient-derived Xenograft (PDX) Models Revenue (US$ Million) & (2019-2024)
        7.1.5 Crown Bioscience Recent Developments
    7.2 Champions Oncology
        7.2.1 Champions Oncology Profile
        7.2.2 Champions Oncology Main Business
        7.2.3 Champions Oncology Patient-derived Xenograft (PDX) Models Products, Services and Solutions
        7.2.4 Champions Oncology Patient-derived Xenograft (PDX) Models Revenue (US$ Million) & (2019-2024)
        7.2.5 Champions Oncology Recent Developments
    7.3 Wuxi Apptec
        7.3.1 Wuxi Apptec Profile
        7.3.2 Wuxi Apptec Main Business
        7.3.3 Wuxi Apptec Patient-derived Xenograft (PDX) Models Products, Services and Solutions
        7.3.4 Wuxi Apptec Patient-derived Xenograft (PDX) Models Revenue (US$ Million) & (2019-2024)
        7.3.5 The Jackson Laboratory Recent Developments
    7.4 The Jackson Laboratory
        7.4.1 The Jackson Laboratory Profile
        7.4.2 The Jackson Laboratory Main Business
        7.4.3 The Jackson Laboratory Patient-derived Xenograft (PDX) Models Products, Services and Solutions
        7.4.4 The Jackson Laboratory Patient-derived Xenograft (PDX) Models Revenue (US$ Million) & (2019-2024)
        7.4.5 The Jackson Laboratory Recent Developments
    7.5 EPO Berlin-Buch
        7.5.1 EPO Berlin-Buch Profile
        7.5.2 EPO Berlin-Buch Main Business
        7.5.3 EPO Berlin-Buch Patient-derived Xenograft (PDX) Models Products, Services and Solutions
        7.5.4 EPO Berlin-Buch Patient-derived Xenograft (PDX) Models Revenue (US$ Million) & (2019-2024)
        7.5.5 EPO Berlin-Buch Recent Developments
    7.6 Oncodesign
        7.6.1 Oncodesign Profile
        7.6.2 Oncodesign Main Business
        7.6.3 Oncodesign Patient-derived Xenograft (PDX) Models Products, Services and Solutions
        7.6.4 Oncodesign Patient-derived Xenograft (PDX) Models Revenue (US$ Million) & (2019-2024)
        7.6.5 Oncodesign Recent Developments
    7.7 Xentech
        7.7.1 Xentech Profile
        7.7.2 Xentech Main Business
        7.7.3 Xentech Patient-derived Xenograft (PDX) Models Products, Services and Solutions
        7.7.4 Xentech Patient-derived Xenograft (PDX) Models Revenue (US$ Million) & (2019-2024)
        7.7.5 Xentech Recent Developments
    7.8 Envigo
        7.8.1 Envigo Profile
        7.8.2 Envigo Main Business
        7.8.3 Envigo Patient-derived Xenograft (PDX) Models Products, Services and Solutions
        7.8.4 Envigo Patient-derived Xenograft (PDX) Models Revenue (US$ Million) & (2019-2024)
        7.8.5 Envigo Recent Developments
    7.9 Charles River Laboratories
        7.9.1 Charles River Laboratories Profile
        7.9.2 Charles River Laboratories Main Business
        7.9.3 Charles River Laboratories Patient-derived Xenograft (PDX) Models Products, Services and Solutions
        7.9.4 Charles River Laboratories Patient-derived Xenograft (PDX) Models Revenue (US$ Million) & (2019-2024)
        7.9.5 Charles River Laboratories Recent Developments
    7.10 Pharmatest Services
        7.10.1 Pharmatest Services Profile
        7.10.2 Pharmatest Services Main Business
        7.10.3 Pharmatest Services Patient-derived Xenograft (PDX) Models Products, Services and Solutions
        7.10.4 Pharmatest Services Patient-derived Xenograft (PDX) Models Revenue (US$ Million) & (2019-2024)
        7.10.5 Pharmatest Services Recent Developments
    7.11 Urosphere
        7.11.1 Urosphere Profile
        7.11.2 Urosphere Main Business
        7.11.3 Urosphere Patient-derived Xenograft (PDX) Models Products, Services and Solutions
        7.11.4 Urosphere Patient-derived Xenograft (PDX) Models Revenue (US$ Million) & (2019-2024)
        7.11.5 Urosphere Recent Developments
    7.12 MEDICILON
        7.12.1 MEDICILON Profile
        7.12.2 MEDICILON Main Business
        7.12.3 MEDICILON Patient-derived Xenograft (PDX) Models Products, Services and Solutions
        7.12.4 MEDICILON Patient-derived Xenograft (PDX) Models Revenue (US$ Million) & (2019-2024)
        7.12.5 MEDICILON Recent Developments
    7.13 Horizon Discovery
        7.13.1 Horizon Discovery Profile
        7.13.2 Horizon Discovery Main Business
        7.13.3 Horizon Discovery Patient-derived Xenograft (PDX) Models Products, Services and Solutions
        7.13.4 Horizon Discovery Patient-derived Xenograft (PDX) Models Revenue (US$ Million) & (2019-2024)
        7.13.5 Horizon Discovery Recent Developments
    7.14 Shanghai Model Organisms Center
        7.14.1 Shanghai Model Organisms Center Profile
        7.14.2 Shanghai Model Organisms Center Main Business
        7.14.3 Shanghai Model Organisms Center Patient-derived Xenograft (PDX) Models Products, Services and Solutions
        7.14.4 Shanghai Model Organisms Center Patient-derived Xenograft (PDX) Models Revenue (US$ Million) & (2019-2024)
        7.14.5 Shanghai Model Organisms Center Recent Developments
    7.15 GemPharmatech
        7.15.1 GemPharmatech Profile
        7.15.2 GemPharmatech Main Business
        7.15.3 GemPharmatech Patient-derived Xenograft (PDX) Models Products, Services and Solutions
        7.15.4 GemPharmatech Patient-derived Xenograft (PDX) Models Revenue (US$ Million) & (2019-2024)
        7.15.5 GemPharmatech Recent Developments
    7.16 LIDE Biotech
        7.16.1 LIDE Biotech Profile
        7.16.2 LIDE Biotech Main Business
        7.16.3 LIDE Biotech Patient-derived Xenograft (PDX) Models Products, Services and Solutions
        7.16.4 LIDE Biotech Patient-derived Xenograft (PDX) Models Revenue (US$ Million) & (2019-2024)
        7.16.5 LIDE Biotech Recent Developments

 8 Industry Chain Analysis
    8.1 Patient-derived Xenograft (PDX) Models Industrial Chain
    8.2 Patient-derived Xenograft (PDX) Models Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Patient-derived Xenograft (PDX) Models Sales Model
        8.5.2 Sales Channel
        8.5.3 Patient-derived Xenograft (PDX) Models Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Patient-derived Xenograft (PDX) Models Market Trends
    Table 2. Patient-derived Xenograft (PDX) Models Market Drivers & Opportunity
    Table 3. Patient-derived Xenograft (PDX) Models Market Challenges
    Table 4. Patient-derived Xenograft (PDX) Models Market Restraints
    Table 5. Global Patient-derived Xenograft (PDX) Models Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Patient-derived Xenograft (PDX) Models Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Patient-derived Xenograft (PDX) Models Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Patient-derived Xenograft (PDX) Models Product Type
    Table 9. Key Companies Time to Begin Mass Production of Patient-derived Xenograft (PDX) Models
    Table 10. Global Patient-derived Xenograft (PDX) Models Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Patient-derived Xenograft (PDX) Models as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Patient-derived Xenograft (PDX) Models Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Patient-derived Xenograft (PDX) Models Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Patient-derived Xenograft (PDX) Models Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Patient-derived Xenograft (PDX) Models Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Patient-derived Xenograft (PDX) Models Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Patient-derived Xenograft (PDX) Models Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Patient-derived Xenograft (PDX) Models Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Patient-derived Xenograft (PDX) Models Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Patient-derived Xenograft (PDX) Models Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Patient-derived Xenograft (PDX) Models Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Patient-derived Xenograft (PDX) Models Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Patient-derived Xenograft (PDX) Models Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Patient-derived Xenograft (PDX) Models Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Patient-derived Xenograft (PDX) Models Sales Value by Region (2019-2024) & (%)
    Table 27. Global Patient-derived Xenograft (PDX) Models Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Patient-derived Xenograft (PDX) Models Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Patient-derived Xenograft (PDX) Models Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Patient-derived Xenograft (PDX) Models Sales Value, (2025-2030) & (US$ Million)
    Table 31. Crown Bioscience Basic Information List
    Table 32. Crown Bioscience Description and Business Overview
    Table 33. Crown Bioscience Patient-derived Xenograft (PDX) Models Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Patient-derived Xenograft (PDX) Models Business of Crown Bioscience (2019-2024)
    Table 35. Crown Bioscience Recent Developments
    Table 36. Champions Oncology Basic Information List
    Table 37. Champions Oncology Description and Business Overview
    Table 38. Champions Oncology Patient-derived Xenograft (PDX) Models Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Patient-derived Xenograft (PDX) Models Business of Champions Oncology (2019-2024)
    Table 40. Champions Oncology Recent Developments
    Table 41. Wuxi Apptec Basic Information List
    Table 42. Wuxi Apptec Description and Business Overview
    Table 43. Wuxi Apptec Patient-derived Xenograft (PDX) Models Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Patient-derived Xenograft (PDX) Models Business of Wuxi Apptec (2019-2024)
    Table 45. Wuxi Apptec Recent Developments
    Table 46. The Jackson Laboratory Basic Information List
    Table 47. The Jackson Laboratory Description and Business Overview
    Table 48. The Jackson Laboratory Patient-derived Xenograft (PDX) Models Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Patient-derived Xenograft (PDX) Models Business of The Jackson Laboratory (2019-2024)
    Table 50. The Jackson Laboratory Recent Developments
    Table 51. EPO Berlin-Buch Basic Information List
    Table 52. EPO Berlin-Buch Description and Business Overview
    Table 53. EPO Berlin-Buch Patient-derived Xenograft (PDX) Models Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Patient-derived Xenograft (PDX) Models Business of EPO Berlin-Buch (2019-2024)
    Table 55. EPO Berlin-Buch Recent Developments
    Table 56. Oncodesign Basic Information List
    Table 57. Oncodesign Description and Business Overview
    Table 58. Oncodesign Patient-derived Xenograft (PDX) Models Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Patient-derived Xenograft (PDX) Models Business of Oncodesign (2019-2024)
    Table 60. Oncodesign Recent Developments
    Table 61. Xentech Basic Information List
    Table 62. Xentech Description and Business Overview
    Table 63. Xentech Patient-derived Xenograft (PDX) Models Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Patient-derived Xenograft (PDX) Models Business of Xentech (2019-2024)
    Table 65. Xentech Recent Developments
    Table 66. Envigo Basic Information List
    Table 67. Envigo Description and Business Overview
    Table 68. Envigo Patient-derived Xenograft (PDX) Models Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Patient-derived Xenograft (PDX) Models Business of Envigo (2019-2024)
    Table 70. Envigo Recent Developments
    Table 71. Charles River Laboratories Basic Information List
    Table 72. Charles River Laboratories Description and Business Overview
    Table 73. Charles River Laboratories Patient-derived Xenograft (PDX) Models Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Patient-derived Xenograft (PDX) Models Business of Charles River Laboratories (2019-2024)
    Table 75. Charles River Laboratories Recent Developments
    Table 76. Pharmatest Services Basic Information List
    Table 77. Pharmatest Services Description and Business Overview
    Table 78. Pharmatest Services Patient-derived Xenograft (PDX) Models Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Patient-derived Xenograft (PDX) Models Business of Pharmatest Services (2019-2024)
    Table 80. Pharmatest Services Recent Developments
    Table 81. Urosphere Basic Information List
    Table 82. Urosphere Description and Business Overview
    Table 83. Urosphere Patient-derived Xenograft (PDX) Models Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Patient-derived Xenograft (PDX) Models Business of Urosphere (2019-2024)
    Table 85. Urosphere Recent Developments
    Table 86. MEDICILON Basic Information List
    Table 87. MEDICILON Description and Business Overview
    Table 88. MEDICILON Patient-derived Xenograft (PDX) Models Products, Services and Solutions
    Table 89. Revenue (US$ Million) in Patient-derived Xenograft (PDX) Models Business of MEDICILON (2019-2024)
    Table 90. MEDICILON Recent Developments
    Table 91. Horizon Discovery Basic Information List
    Table 92. Horizon Discovery Description and Business Overview
    Table 93. Horizon Discovery Patient-derived Xenograft (PDX) Models Products, Services and Solutions
    Table 94. Revenue (US$ Million) in Patient-derived Xenograft (PDX) Models Business of Horizon Discovery (2019-2024)
    Table 95. Horizon Discovery Recent Developments
    Table 96. Shanghai Model Organisms Center Basic Information List
    Table 97. Shanghai Model Organisms Center Description and Business Overview
    Table 98. Shanghai Model Organisms Center Patient-derived Xenograft (PDX) Models Products, Services and Solutions
    Table 99. Revenue (US$ Million) in Patient-derived Xenograft (PDX) Models Business of Shanghai Model Organisms Center (2019-2024)
    Table 100. Shanghai Model Organisms Center Recent Developments
    Table 101. GemPharmatech Basic Information List
    Table 102. GemPharmatech Description and Business Overview
    Table 103. GemPharmatech Patient-derived Xenograft (PDX) Models Products, Services and Solutions
    Table 104. Revenue (US$ Million) in Patient-derived Xenograft (PDX) Models Business of GemPharmatech (2019-2024)
    Table 105. GemPharmatech Recent Developments
    Table 106. LIDE Biotech Basic Information List
    Table 107. LIDE Biotech Description and Business Overview
    Table 108. LIDE Biotech Patient-derived Xenograft (PDX) Models Products, Services and Solutions
    Table 109. Revenue (US$ Million) in Patient-derived Xenograft (PDX) Models Business of LIDE Biotech (2019-2024)
    Table 110. LIDE Biotech Recent Developments
    Table 111. Key Raw Materials Lists
    Table 112. Raw Materials Key Suppliers Lists
    Table 113. Patient-derived Xenograft (PDX) Models Downstream Customers
    Table 114. Patient-derived Xenograft (PDX) Models Distributors List
    Table 115. Research Programs/Design for This Report
    Table 116. Key Data Information from Secondary Sources
    Table 117. Key Data Information from Primary Sources
    Table 118. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Patient-derived Xenograft (PDX) Models Product Picture
    Figure 2. Global Patient-derived Xenograft (PDX) Models Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Patient-derived Xenograft (PDX) Models Sales Value (2019-2030) & (US$ Million)
    Figure 4. Patient-derived Xenograft (PDX) Models Report Years Considered
    Figure 5. Global Patient-derived Xenograft (PDX) Models Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Patient-derived Xenograft (PDX) Models Revenue in 2023
    Figure 7. Patient-derived Xenograft (PDX) Models Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Mouse Model Picture
    Figure 9. Rat Model Picture
    Figure 10. Global Patient-derived Xenograft (PDX) Models Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 11. Global Patient-derived Xenograft (PDX) Models Sales Value Market Share by Type, 2023 & 2030
    Figure 12. Product Picture of Preclinical Drug development
    Figure 13. Product Picture of Biomarker Analysis
    Figure 14. Global Patient-derived Xenograft (PDX) Models Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 15. Global Patient-derived Xenograft (PDX) Models Sales Value Market Share by Application, 2023 & 2030
    Figure 16. North America Patient-derived Xenograft (PDX) Models Sales Value (2019-2030) & (US$ Million)
    Figure 17. North America Patient-derived Xenograft (PDX) Models Sales Value by Country (%), 2023 VS 2030
    Figure 18. Europe Patient-derived Xenograft (PDX) Models Sales Value (2019-2030) & (US$ Million)
    Figure 19. Europe Patient-derived Xenograft (PDX) Models Sales Value by Country (%), 2023 VS 2030
    Figure 20. Asia Pacific Patient-derived Xenograft (PDX) Models Sales Value (2019-2030) & (US$ Million)
    Figure 21. Asia Pacific Patient-derived Xenograft (PDX) Models Sales Value by Country (%), 2023 VS 2030
    Figure 22. South America Patient-derived Xenograft (PDX) Models Sales Value (2019-2030) & (US$ Million)
    Figure 23. South America Patient-derived Xenograft (PDX) Models Sales Value by Country (%), 2023 VS 2030
    Figure 24. Middle East & Africa Patient-derived Xenograft (PDX) Models Sales Value (2019-2030) & (US$ Million)
    Figure 25. Middle East & Africa Patient-derived Xenograft (PDX) Models Sales Value by Country (%), 2023 VS 2030
    Figure 26. Key Countries/Regions Patient-derived Xenograft (PDX) Models Sales Value (%), (2019-2030)
    Figure 27. United States Patient-derived Xenograft (PDX) Models Sales Value, (2019-2030) & (US$ Million)
    Figure 28. United States Patient-derived Xenograft (PDX) Models Sales Value by Type (%), 2023 VS 2030
    Figure 29. United States Patient-derived Xenograft (PDX) Models Sales Value by Application (%), 2023 VS 2030
    Figure 30. Europe Patient-derived Xenograft (PDX) Models Sales Value, (2019-2030) & (US$ Million)
    Figure 31. Europe Patient-derived Xenograft (PDX) Models Sales Value by Type (%), 2023 VS 2030
    Figure 32. Europe Patient-derived Xenograft (PDX) Models Sales Value by Application (%), 2023 VS 2030
    Figure 33. China Patient-derived Xenograft (PDX) Models Sales Value, (2019-2030) & (US$ Million)
    Figure 34. China Patient-derived Xenograft (PDX) Models Sales Value by Type (%), 2023 VS 2030
    Figure 35. China Patient-derived Xenograft (PDX) Models Sales Value by Application (%), 2023 VS 2030
    Figure 36. Japan Patient-derived Xenograft (PDX) Models Sales Value, (2019-2030) & (US$ Million)
    Figure 37. Japan Patient-derived Xenograft (PDX) Models Sales Value by Type (%), 2023 VS 2030
    Figure 38. Japan Patient-derived Xenograft (PDX) Models Sales Value by Application (%), 2023 VS 2030
    Figure 39. South Korea Patient-derived Xenograft (PDX) Models Sales Value, (2019-2030) & (US$ Million)
    Figure 40. South Korea Patient-derived Xenograft (PDX) Models Sales Value by Type (%), 2023 VS 2030
    Figure 41. South Korea Patient-derived Xenograft (PDX) Models Sales Value by Application (%), 2023 VS 2030
    Figure 42. Southeast Asia Patient-derived Xenograft (PDX) Models Sales Value, (2019-2030) & (US$ Million)
    Figure 43. Southeast Asia Patient-derived Xenograft (PDX) Models Sales Value by Type (%), 2023 VS 2030
    Figure 44. Southeast Asia Patient-derived Xenograft (PDX) Models Sales Value by Application (%), 2023 VS 2030
    Figure 45. India Patient-derived Xenograft (PDX) Models Sales Value, (2019-2030) & (US$ Million)
    Figure 46. India Patient-derived Xenograft (PDX) Models Sales Value by Type (%), 2023 VS 2030
    Figure 47. India Patient-derived Xenograft (PDX) Models Sales Value by Application (%), 2023 VS 2030
    Figure 48. Patient-derived Xenograft (PDX) Models Industrial Chain
    Figure 49. Patient-derived Xenograft (PDX) Models Manufacturing Cost Structure
    Figure 50. Channels of Distribution (Direct Sales, and Distribution)
    Figure 51. Bottom-up and Top-down Approaches for This Report
    Figure 52. Data Triangulation

Description

The global market for Patient-derived Xenograft (PDX) Models was estimated to be worth US$ 331.6 million in 2023 and is forecast to a readjusted size of US$ 588.6 million by 2030 with a CAGR of 8.5% during the forecast period 2024-2030
Global top 5 manufacturers of patient-derived xenograft (PDX) models occupied for a share nearly 45 percent, key players are Crown Bioscience, Champions Oncology, Wuxi Apptec, EPO Berlin-Buch, and Oncodesign, etc. Geographically speaking, Asia Pacific holds the most of global market share, about 35%. North America holds about 30% of share, while Europe followed by nearly 20%. In terms of type, mouse model accounted for nearly 75%, and rat model accounted for a share of 25%,The application of patient-derived xenograft (PDX) models includes preclinical drug development and biomarker analysis. Preclinical drug development shares over 75%, while biomarker analysis shares about 20%.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Patient-derived Xenograft (PDX) Models, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Patient-derived Xenograft (PDX) Models by region & country, by Type, and by Application.

The Patient-derived Xenograft (PDX) Models market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Patient-derived Xenograft (PDX) Models.

Market Segmentation